OneSource Speci. Q4 FY26 Earnings Call — Analysis (NSE: ONESOURCE)

OneSource Specialty Pharma posted a sharp Q4FY26 sequential recovery with revenue up 47% QoQ to ₹428.2 Cr, driven by the long-awaited India Semaglutide launch, and reiterated its FY28 guidance of US$400 million organic revenue and ~40% EBITDA margins.

28 Jun 2026 · Analysis by Alpha Inflection

The take

FY26 Revenue ₹1,421.6 Cr ( −2% decline YoY ) , Q4FY26 +47% . Guidance raised — FY28 biologics revenue in fy28 meaningful . But walked back — Inorganic Integration & Scale . New story: Capacity Build-out Arms Race .

Financial highlights

What management committed to

• Our second [DDC manufacturing] line will be available for commercialization in the next quarter [Q2FY27]. — Q2FY27
• By end of FY27, we will have three [DDC manufacturing] lines installed. — 3 lines, FY27
• The Third [DDC] line will be coming online later in the year [FY27]. — FY27
• The Steriscience and Brooks acquisition scheme is deferred for approximately two years; we will re-look at [the transaction] then. — FY29
• A fourth line [dedicated injectable] is coming in unit two [SPD site] with high-viscosity pre-filled syringes capability. — FY28
• The new [DDC] lines can go up to between 750 to 1,000 liters batch size. — 750-1,000 liters, Q2FY27
• Commercial manufacturing for biologics will start from FY29 onwards. — FY29
• The biologics business will already contribute meaningfully in FY28 [revenue]. — meaningful, FY28
• We have a fourth line coming in unit two [SPD], which is a dedicated injectable capability. — FY28

How the narrative shifted

• Regulatory Ambiguity & Revenue-Recognition Gap: Shift from 'delays causing deferral' to 'approvals are now arriving, demonstrating proof of concept' — the gap is being resolved.
• Capacity Build-out Arms Race: More specific timelines and line counts provided; the narrative shifted from 'progressing' to 'installed and qualifying' — closer to reality.
• Geographic & Customer De-risking Beyond Canada: Now has concrete proof points (India day-one launch, two Canadian approvals) to back the claim, rather than just aspiration.
• Biologics Resurgence as Second Engine: Funnel growth quantified (4x), specific customer wins named; timeline for commercial revenue pushed slightly further out but reinforced as a long-term growth driver.
• Inorganic Integration & Scale: Complete pivot from 'proceeding toward Q3FY27 approvals' to 'deferred indefinitely, on back burner' — a major setback spun as 'governance-focused' and 'temporary.'
• CDMO Moat: End-to-End & Multi-Modality: Integrated offering (sterile injectable, DDC, biologics, soft gel) continues to resonate; end-to-end service including assembly is a differentiator.
• Semaglutide Global TAM Inflection: Now backed by India market share data and multiple commercial launches; narrative shifted from 'anticipation' to 'real proof.'
• Working Capital & Debt Transience: Cost of borrowing improved (below 9%, down 210 bps) — a positive data point supporting the thesis.
• Sterile Injectable Capacity Upgrade & Shutdown: No mention of the shutdown impact; the upgrade is now framed as capacity addition rather than disruption.
• Partner Collaboration & Contract Flexibility: Less emphasis on contract flexibility; instead, focus on contracted take-or-pay securing demand visibility.

Operational commentary

• India Semaglutide launch: partners present on day one across multiple brands; as of end-April, OneSource customers held ~2/3rds of the generic Semaglutide market by value.
• Canada: back-to-back approvals for two partners (Dr. Reddy’s and Orbicular with a Canadian partner), first and only CDMO for the first three generic Semaglutide approvals in US and Canada.
• US: tentative approval received for one partner.
• Emerging markets: approvals expected to follow the Indian approval; Saudi launch imminent, ANVISA approval secured, multiple customer filings in Brazil/Turkey/Saudi Arabia.
• Capacity expansion: second DDC line installed and in qualification, expected to be available for commercial production in Q2FY27. A third line to be added by end of FY27, bringing total to three lines.
• Biologics: funnel expanded ~4x vs. previous year; added a European biosimilar partner, a US biosimilar major, and a second project from a top-three global animal health company.
• Base business (injectables & soft gels): 10 new licensing/CDMO deals signed, 15+ products launched, sterile injectable capability deepened with SPD suite.
• Compliance: 49 regulatory/customer audits in FY26, including two unannounced FDA inspections—both cleared with EIRs; EU GMP renewed; ANVISA approval obtained.
• People & ESG: added ~400 people at the flagship site for expansion; received EcoVadis bronze medal; recognized as leader on NSE sustainability ratings.
• Scheme deferral: the previously announced scheme to bring in Steriscience injectables and Brooks business has been paused, to be re-evaluated in about two years once both entities deliver on their respective targets.

Analyst Q&A

• Q. Will there be similar profit-sharing arrangements with other customers in major regulated markets?

  As a CDMO, we do not discuss specific customers or terms; confidentiality is the biggest part of our deal with customers.

• Q. Can you provide quantitative FY27 revenue or earnings guidance?

  We will stay right now with FY28 guidance while we continue to progress with commercial launches and expanding capacities. This year we are reiterating FY28.

• Q. What is the revenue and EBITDA loss for the biologics business in FY26, and when will it break even?

  We don't break down business-wise revenue or profitability due to customer confidentiality and because modalities are taken together.

• Q. What is the timeline for approvals of your other clients in the Canadian market?

  We are not directly involved in regulatory strategy; Health Canada has indicated more approvals in the pipeline, but exact timing is difficult to anticipate.

• Q. What kind of revenue scale will the current elevated staff and opex investments support?

  These investments are for supporting our capacity expansion and are aimed at delivering our US$400 million revenue guidance.

• Q. Do you have minimum volume commitments from clients for Semaglutide supply?

  Yes, customers have reserved capacity with upfront fees and take-or-pay contracts; the challenge is access to capacity.

Research and educational content only. Not investment advice.